Pharmaceutical

Nelivaptan by HMNC for Major Depressive Disorder: Likelihood of Approval

Nelivaptan is under clinical development by HMNC and currently in Phase II for Major Depressive Disorder.

Dec 27, 2024 - 06:00
Nelivaptan is under clinical development by HMNC and currently in Phase II for Major Depressive Disorder.
Read the original article

Tags:

Previous Article

Gene Therapy to Target GD2 for Oncology by Bristol-Myers Squibb for Sarcomas: Li...

Next Article

Darigabat by Cerevel Therapeutics for Seizures: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Novaliq pursues EMA approval for dry eye disease drug

Novaliq pursues EMA approval for dry eye disease drug

Aug 24, 2023

Signal: LimmaTech raises $37m for antimicrobial resistance research

Signal: LimmaTech raises $37m for antimicrobial resista...

Oct 9, 2023

Covid-19 increases risk of developing autoimmune disease, but vaccination helps, large study shows

Covid-19 increases risk of developing autoimmune diseas...

Mar 4, 2024